

REMARKS

This Amendment is filed in response to the Office Action mailed June 30, 2010. In this Amendment, independent claims 13, 16 and 25 are amended. Claims 1-12 were previously withdrawn, claim 29 was previously canceled, and claims 14-15, 17, 19-21 and 24 are unchanged. Following entry of this amendment, claims 14-17, and 19-28 shall be pending.

I. CLAIM REJECTION UNDER 35 USC § 112

Claim 16 was rejected under § 112 on grounds that the phrase "the relatively high viscosity liquid" had insufficient antecedent basis in the parent claim 15. To overcome this rejection, the phrase "relatively high viscosity" has been deleted from claim 16. The claim refers simply to "the liquid" of claim 15 and is now supported thereby.

II. CLAIM REJECTIONS UNDER 35 USC § 102

Claims 13 and 17-21, and 25-28 have been rejected under § 102(b) as being anticipated by US 5,669,931 ("Kupiecki"). Applicants would like to cordially thank Examiner Mashak for the telephonic interview conducted on 24 September, 2010, with Attorney for the Applicants, David McKinley. During the interview, it was discussed that amending the independent claims 13 and 25 to clarify that the introducing steps recite introducing the deployment tube intravascularly proximal the target vascular site while the coupling element of the endovascular device is attached to the deployment tube, and a distal portion of the endovascular device is distal of the deployment tube, would overcome the § 102 rejections as being anticipated by *Kupiecki*.

All of the remaining claims rejected under § 102 depend, directly or indirectly, from claims 13 or 25 and thus are patentable for at least the reasons discussed at the interview. However, they are independently patentable as well. In light of the amendments made, the Applicants respectfully request that these rejections be withdrawn.

III. REJECTIONS UNDER 35 USC § 103

Claim 13 is rejected under 35 USC § 103(a) as being unpatentable over US 6,015,424 ("*Rosenbluth*") in view of US 6,514,264 ("*Naglireiter*"). During the telephonic interview, it was also argued that the rejections made under § 103 over *Rosenbluth* in view of *Naglireiter* were improper and Examiner Mashak indicated that they would be withdrawn. Applicants thank Examiner Mashak for this indication. Moreover, claim 13 has been amended to overcome the § 102 rejection, which amendment further distinguishes the claim from *Naglireiter* and *Rosenbluth*. Withdrawal of this rejection is requested.

Claims 14 and 22 are rejected under § 103(a) as being unpatentable over *Kupiecki* in view of 6,117,142 ("*Goodson*"). The applicant respectfully submits that this rejection has been overcome at least by the amendment to claim 13, from which claims 14 and 22 depend. Claims 14 and 22 are independently patentable as well. Withdrawal of these rejections is requested.

Claims 14 and 22-24 are rejected under 35 USC § 103(a) as being unpatentable over *Rosenbluth* in view of *Naglireiter* in further view of US 6,063,070 ("*Eder*"). As stated above, during the telephonic interview, it was also argued that the rejections made under § 103 over *Rosenbluth* in view of *Naglireiter* were improper and Examiner Mashak indicated that they would be withdrawn. Applicants thank Examiner Mashak for this indication. Moreover, claim 13 has been amended to overcome the § 102 rejection, which amendment further distinguishes the claim from *Naglireiter* and *Rosenbluth*. Withdrawal of these rejections is also requested.

Claims 15-16 are rejected under § 103(a) as being unpatentable over *Kupiecki* in view of 6,224,609 ("*Resseman*"). The applicant respectfully submits that this rejection has been overcome at least by the amendment to claim 13, from which claims 15-16 depend. Claims 15-16 are independently patentable as well. Withdrawal of these rejections is requested.

CONCLUSION


In view of the foregoing, it is submitted that pending claims 13-17 and 19-28 are now in condition for allowance. Hence, an indication of allowability is hereby requested.

If for any reason direct communication with Applicants' attorney would serve to advance prosecution of this case to finality, the Examiner is cordially urged to call the undersigned attorney at the below listed telephone number.

The Commissioner is authorized to charge any fee which may be required in connection with this Amendment to deposit account No. 50-2809.

Respectfully submitted,

Dated: October 29, 2010



David J. McKinley
Registration No. 42,867

INSKEEP INTELLECTUAL PROPERTY GROUP, INC.
Inskeep Intellectual Property Group, Inc.
2281 W. 190th Street, Suite 200
Torrance, CA 90504
Phone: 310-755-7800
Fax: 310-327-3466

Customer No. 37,374